Navigation Links
Metabolex Announces Election of Kurt von Emster to Board of Directors
Date:4/22/2009

HAYWARD, Calif., April 22 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Kurt von Emster has been elected to its Board of Directors.

Mr. von Emster currently serves as a Managing Director of venBio. From November 2000 to March 2009, Mr. von Emster was Managing Director of MPM BioEquities and a Portfolio Manager for the MPM BioEquities Fund. From July 1989 to November 2000, Mr. von Emster was with the Franklin Templeton Group, most recently as a Vice President and Portfolio Manager. Mr. von Emster is currently a member of the board of directors at Somaxon Pharmaceuticals, Inc., and Facet Biotech, both public biotechnology companies. Mr. von Emster is a Chartered Financial Analyst (CFA), a member of the Association for Investment Management and Research and of the Security Analysts of San Francisco. Mr. von Emster received his B.S. degree from the University of California at Santa Barbara.

"Mr. von Emster brings to the Board the perspective of a seasoned private and public company investor," said Harold Van Wart, Ph.D., president and chief executive officer of Metabolex. "We look forward to his input and expertise as the company continues to build upon its recent clinical successes." Mr. von Emster's appointment follows the resignation of Rob Chess from the Board of Directors. Dr. Van Wart added, "I would like to thank Rob for his many valuable contributions to Metabolex during his Board tenure."

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes in
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
3. Metabolex Names Zhao, Martin to Executive Posts
4. Metabolex Appoints Donald Hill as Chief Financial Officer
5. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
6. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
9. E&K Scientific Announces New Accuflow Product Line
10. Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
11. International Society for Medical Publication Professionals (ISMPP) Announces First CMPP Exam Window Closes, Next Opportunity in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, ... aesthetic products for skin and hair rejuvenation, has ... as agency of record for investor relations and ... improve our distribution, sales and diversification strategies – ... current and prospective shareholders," stated Ali Kharazmi CEO ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Innovation ... are emerging from unexpected parts of the world ... From agriculture to manufacturing to health care, ... and environmental realities and socio-political trends shake the ... the key ingredient for CEOs to survive the ...
(Date:2/26/2015)... 26, 2015 Ceres, Inc . today ... Oracle PartnerNetwork. In attaining Gold Level membership, Ceres has ... Oracle-related knowledge in delivering Ceres, Persephone genome visualization software ... Originally developed for in-house use by Ceres, ... and out of massive amounts of genetic data, from ...
(Date:2/26/2015)... SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2015 ... for the treatment of cancer, today announced that ... present a corporate overview at the upcoming Cowen and ... Boston . Dr. McCarthy,s presentation will ... 2. About CytomX Therapeutics CytomX Therapeutics ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... EMERYVILLE, Calif., Feb. 7 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... quarter 2008 financial results, for the quarter ended December,31, ... conference call to,discuss the earnings and to give a ... E. Freiman, President and Chief Executive,Officer, and Craig W. ...
... -- Total segment operating profit increased 77% when compared to the same ... 14% volume growth in the quarter, -- Fertilizer continued to benefit ... (In millions, except per share data and percentages), ... Quarter Ended ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... Company,s marketing-enabling bioequivalence clinical study of ANX-530,(vinorelbine ... the 2008,American Association for Cancer Research (AACR) ... 16, 2008 in San Diego, CA., ...
Cached Biology Technology:Bunge Reports Fourth Quarter Net Income of $245 Million 2Bunge Reports Fourth Quarter Net Income of $245 Million 3Bunge Reports Fourth Quarter Net Income of $245 Million 4Bunge Reports Fourth Quarter Net Income of $245 Million 5Bunge Reports Fourth Quarter Net Income of $245 Million 6Bunge Reports Fourth Quarter Net Income of $245 Million 7Bunge Reports Fourth Quarter Net Income of $245 Million 8Bunge Reports Fourth Quarter Net Income of $245 Million 9Bunge Reports Fourth Quarter Net Income of $245 Million 10Bunge Reports Fourth Quarter Net Income of $245 Million 11Bunge Reports Fourth Quarter Net Income of $245 Million 12Bunge Reports Fourth Quarter Net Income of $245 Million 13Bunge Reports Fourth Quarter Net Income of $245 Million 14Bunge Reports Fourth Quarter Net Income of $245 Million 15Bunge Reports Fourth Quarter Net Income of $245 Million 16Bunge Reports Fourth Quarter Net Income of $245 Million 17Bunge Reports Fourth Quarter Net Income of $245 Million 18Bunge Reports Fourth Quarter Net Income of $245 Million 19Bunge Reports Fourth Quarter Net Income of $245 Million 20ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... (December 1, 2010) University of Minnesota School of ... international group of researchers that has identified 30 new ... in women. Many of these genes are also known ... to the multi-institutional study, only four genes had been ...
... If you think life,s too short, then you,re not alone. A team ... to live a very long life and they made important discoveries that ... featured on the cover of The FASEB Journal ( http://www.fasebj.org ... elegans , and in the process discovered a new metabolic state correlating ...
... new class of sensors able to detect multiple ... may soon be within reach thanks to the ... by Georgia Institute of Technology engineers. ... because of their applications in clinical screening, drug ...
Cached Biology News:U of M researcher helps unlock 30 new genes responsible for early onset puberty 2Longevity breakthrough: The metabolic state of mitochondria controls life span 2$4.3 million DARPA grant enables development of biological and chemical threat detector 2$4.3 million DARPA grant enables development of biological and chemical threat detector 3
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... exhibits very high activity in primer extension ... the quality of the enzyme, each lot ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ,• ... which exhibits very high activity in primer ... ensure the quality of the enzyme, each ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Biology Products: